Markers of Minimal Residual Disease

  • A. M. Neville
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 80)

Summary

Current methods employing tumour markers to detect small amounts of residual disease are reviewed with respect to human germ cell, colorectal and breast neoplasms. It is concluded that the assay of tumour markers in body fluids has only limited clinical value. Alternative approaches, such as are afforded by radioimmu nodetection and immunocytochemistry, are presented and critically appraised.

Keywords

Iodine Myeloma Nash Teratoma Hine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bagshawe, KD (1973) Recent observations related to the chemotherapy and immunology of gestational choriocarcinoma. Adv Cancer Res 18:231PubMedCrossRefGoogle Scholar
  2. 2.
    Coombes RC, Gazet JC, Ford HT, Powles TJ, Nash AG, McKinna A, Neville AM (1980) Treatment of malignant disease. Assessment of biochemical tests to screen for metastases in patients with breast cancer. Lancet 1:296–297PubMedCrossRefGoogle Scholar
  3. 3.
    Dykes PW, Hine KR, Bradwell AR, Blackburn JC, Reeder TA, Drolc Z, Booth SN (1980) Localisation of tumour deposits by external scanning after injection of radiolabeled anti-carcinoembryonic antigen. Br Med J 280:220–222PubMedCrossRefGoogle Scholar
  4. 4.
    Goldenberg DM, DeLand F, Euishin K, Bennett S, Primus FJ, van Nagell JR, Estes M, DeSimone P (1978) Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 298:1384–1388PubMedCrossRefGoogle Scholar
  5. 5.
    Herlyn M, Steplewksi Z, Herlyn D, Koprowski H (1979) Colorectal carcinoma-specific antigen: Detection by means of monoclonal antibodies. Proc Natl Acad Sci USA 76: 1438–1442PubMedCrossRefGoogle Scholar
  6. 6.
    Heyderman E, Steele K, Ormerod MG (1979) A new antigen on the epithelial membrane: Its immunoperoxidase localisation in normal and neoplastic tissue. J Clin Pathol 32:35–39PubMedCrossRefGoogle Scholar
  7. 7.
    Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497PubMedCrossRefGoogle Scholar
  8. 8.
    Kohn J (1979) The value of apparent half-life assay of alpha-1 fetoprotein in the management of testicular teratoma. In: Lehmann FG (ed) Carcinoembryonic proteins, vol 2. Elsevier/North-Holland Biomedical Press, Amsterdam, p 383Google Scholar
  9. 9.
    Laurence DJR, Neville AM (1980) Biochemical tests in diagnosis and monitoring of cancer. In: Goldberg DM (ed) Annual review of clinical biochemistry, vol 1. Wiley, New York, p 185Google Scholar
  10. 10.
    Martin EW Jr, Cooperman M, King G, Rinker L, Carey LC, Minton JP (1979) A retrospective and prospective study of serial CEA determinations in the early detection of recurrent colon cancer. Am J Surg 137: 167–169PubMedCrossRefGoogle Scholar
  11. 11.
    Moertel CG, Schutt AJ, Go VLW (1978) Carcinoembryonic antigen test for recurrent colorectal carcinoma. JAMA 239:1065–1066PubMedCrossRefGoogle Scholar
  12. 12.
    Neville AM, Cooper EH (1976) Biochemical monitoring of cancer. Ann Clin Biochem 13:283–305PubMedGoogle Scholar
  13. 13.
    Neville AM, Patel S, Capp M, Laurence DJR, Cooper EH, Turberville C, Coombes RC (1978) Longterm follow-up of colorectal carcinoma patients by repeated CEA radioimmunoassay. Cancer 42:1448–1451PubMedCrossRefGoogle Scholar
  14. 14.
    Raghavan D, Gibbs J, Nogueira Cost R, Kohn J, Orr AH, Barrett A, Peckham MJ (1980) The interpretation of marker protein assays: A critical appraisal in clinical studies and a xenograft model. Br J Cancer [Suppl4] 41:191–194Google Scholar
  15. 15.
    Sloane JO, Ormerod MG, Neville AM (to be published) Potential pathological application of immunocytochemical methods to the detection of micrometastases. Cancer Res 40Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1982

Authors and Affiliations

  • A. M. Neville
    • 1
  1. 1.Ludwig Institute for Cancer ResearchRoyal Marsden HospitalSuttonUK

Personalised recommendations